Imcyse raises •35M in series B funding and additional grants
Imcyse completes enrolment in Phase lb trial of Imotopes
Drug Discovery News on Twitter: "Thanks to #Imcyse's @JeanRampelbergh & @Innodiagroup's Chantal Mathieu for their thoughts on type 1 #diabetes Learn about their efforts in our October Special Report https://t.co/sGHUqYaaMz https://t.co/tzyyiZRBu6 ...
Imcyse - ImotopesTM autoimmune disease treatment
Imcyse's €35M Series B to Fund Potential Type 1 Diabetes Cure
IMPACT Study – T1DUK
Imcyse - Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy - YouTube
BERNAMA - Beware Of Risk Of Diabetes In Children Infected By COVID-19
Colin Dayan - Media Centre | EASD
Articles with Imcyse
Belgium-based biotech startup Imcyse secures €35M Series B funding, a hope to patients with chronic diabetes | Silicon Canals
Imcyse - Rethinking T1D: Saving Beta Cells with Targeted Immunotherapy - YouTube
Imcyse - Portfolio
Veranstaltungen zum Thema Typ-1-Diabetes - INNODIA
Diabetology | Free Full-Text | Novel Insights into the Immunotherapy-Based Treatment Strategy for Autoimmune Type 1 Diabetes
Towards a first precision medicine Immunotherapy for the treatment of Type 1 Diabetes using Ariana's Artificial Intelligence - Ariana Pharma
Imcyse's Type 1 Diabetes Immunotherapy Shows Promise in Phase I
Imcyse's Type 1 Diabetes Immunotherapy Shows Promise in Phase I
Imcyse - Technology Platform
Imcyse - Imcyse Announces Start of Phase 1b/2a IMPACT Study in Patients with Recent Onset Type 1 Diabetes
Belgian Biotech Starts Human Trials for a Potential Type 1 Diabetes Cure
Imcyse's €35M Series B to Fund Potential Type 1 Diabetes Cure
Imcyse SA -
